Roy Buchanan

Stock Analyst at JMP Securities

(0)
# 4719
Out of 5,370 analysts
72
Total ratings
35.00%
Success rate
-16.19%
Average return
18 Stocks
Name Action PT Current % Upside Ratings Updated
ENTA Enanta Pharma
Maintains: Market Outperform
23 24
7.21 232.87% 13 Jun 3, 2025
CDTX Cidara Therapeutics
Reiterates: Market Outperform
47 47
22.18 111.9% 5 Jun 2, 2025
CVAC CureVac
Reiterates: Market Outperform
10 10
5.54 80.51% 9 May 28, 2025
DVAX Dynavax Technologies
Maintains: Market Outperform
33 31
10.03 209.07% 6 May 7, 2025
ANTX AN2 Therapeutics
Maintains: Market Outperform
5 2
1.11 80.18% 9 May 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
18 18
2 800% 3 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
n/a
n/a n/a 1 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
7 4
1.16 244.83% 3 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
23 14
0.65 2053.85% 1 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
33 33
6.58 401.52% 1 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
24 7
1.45 382.76% 2 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 5 Oct 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
4 5
3.52 42.05% 5 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 3 Jul 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
443 448
544.81 -17.77% 2 Mar 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
14 16
14.37 11.34% 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Feb 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Outperform
420
3.55 11730.99% 1 Sep 14, 2021